AG
AQST icon

Advisor Group’s Aquestive Therapeutics AQST Stock Holding History

Advisor Group’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1K Sell
160
-3,546
-96% -$18.4K ﹤0.01% 5091
2019
Q3 		$12K Buy
+3,706
New +$13.9K ﹤0.01% 4232

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $5.53B AUM 25.79% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Advisor Group's AQST Position: Q4 2019 in Review

Advisor Group reduced its Aquestive Therapeutics (AQST) stake by 96% in Q4 2019, selling an estimated $18.4K and leaving 160 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #5091.

Advisor Group first reported a position in AQST in Q3 2019 and has held it in 2 quarters since. The position peaked at $12K in Q3 2019. 56 funds tracked by Wall St. Rank hold AQST as of Q4 2019.

  • Advisor Group held 160 shares of Aquestive Therapeutics worth $1K as of Q4 2019.
  • Advisor Group sold 3,546 Aquestive Therapeutics shares in Q4 2019, an estimated $18.4K.
  • Aquestive Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5091 holding.
  • Advisor Group first reported a position in Aquestive Therapeutics in Q3 2019 and has held it in 2 quarters since.
  • Advisor Group's Aquestive Therapeutics position peaked at $12K in Q3 2019.
  • 56 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.